DLBCL: Clinical Trials

5 trials for DLBCL, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 terminated. 5 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 5
Phase 13Terminated 3

Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
Defibrotide - DLBCL, Neurotoxicity Syndromes
Phase 2TerminatedJazz Pharmaceuticals252019-10-042021-12-09
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
imvotamab - Non-Hodgkin Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2TerminatedIGM Biosciences, Inc.972019-09-302024-07-24
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
Entospletinib, Rituximab, Cyclophosphamide - DLBCL
Phase 1 / Phase 2TerminatedThe Lymphoma Academic Research Organisation252017-07-262020-09-02
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
acalabrutinib, vistusertib - DLBCL, Richter Syndrome
Phase 1 / Phase 2TerminatedAcerta Pharma BV252017-06-292021-01-06
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
90Y-DOTATOC - DLBCL, MCL
Phase 2TerminatedIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS12016-12-222018-03-19

Narrower conditions

Lymphoma, Mantle-Cell (2)  ·  Recurrence (2)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Neurotoxicity Syndromes (1)

Broader conditions

Disease Attributes (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Chemically-Induced Disorders (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Nervous System Diseases (1)

Interventions

6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1)  ·  90Y-octreotide, DOTA-Tyr(3)- (1)  ·  Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  Vincristine (1)  ·  acalabrutinib (1)  ·  defibrotide (1)  ·  vistusertib (1)

Sponsors

Acerta Pharma BV (1)  ·  IGM Biosciences, Inc. (1)  ·  Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1)  ·  Jazz Pharmaceuticals (1)  ·  The Lymphoma Academic Research Organisation (1)

Countries

United States (3)  ·  France (2)  ·  Italy (2)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Emmanuelle Tchernonog (1)  ·  Gilles Salles (1)  ·  Julien Depaus (1)  ·  Maddalena Sansovini, MD (1)

Results publications

PMID 33750072, PMID 34269152, PMID 37399456